Mechanisms behind the immunoregulatory dialogue between mesenchymal stem cells and th17 cells

Simple item page
dc.coverageDOI: 10.3390/cells9071660
dc.creatorTerraza-Aguirre, Claudia
dc.creatorCampos-Mora, Mauricio
dc.creatorElizondo-Vega, Roberto
dc.creatorContreras-López, Rafael A.
dc.creatorLuz-Crawford, Patricia
dc.creatorJorgensen, Christian
dc.creatorDjouad, Farida
dc.date2020
dc.date.accessioned2025-11-18T19:47:35Z
dc.date.available2025-11-18T19:47:35Z
dc.description<p>Mesenchymal stem cells (MSCs) exhibit potent immunoregulatory abilities by interacting with cells of the adaptive and innate immune system. In vitro, MSCs inhibit the differentiation of T cells into T helper 17 (Th17) cells and repress their proliferation. In vivo, the administration of MSCs to treat various experimental inflammatory and autoimmune diseases, such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, and bowel disease showed promising therapeutic results. These therapeutic properties mediated by MSCs are associated with an attenuated immune response characterized by a reduced frequency of Th17 cells and the generation of regulatory T cells. In this manuscript, we review how MSC and Th17 cells interact, communicate, and exchange information through different ways such as cell-to-cell contact, secretion of soluble factors, and organelle transfer. Moreover, we discuss the consequences of this dynamic dialogue between MSC and Th17 well described by their phenotypic and functional plasticity.</p>eng
dc.descriptionMesenchymal stem cells (MSCs) exhibit potent immunoregulatory abilities by interacting with cells of the adaptive and innate immune system. In vitro, MSCs inhibit the differentiation of T cells into T helper 17 (Th17) cells and repress their proliferation. In vivo, the administration of MSCs to treat various experimental inflammatory and autoimmune diseases, such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, and bowel disease showed promising therapeutic results. These therapeutic properties mediated by MSCs are associated with an attenuated immune response characterized by a reduced frequency of Th17 cells and the generation of regulatory T cells. In this manuscript, we review how MSC and Th17 cells interact, communicate, and exchange information through different ways such as cell-to-cell contact, secretion of soluble factors, and organelle transfer. Moreover, we discuss the consequences of this dynamic dialogue between MSC and Th17 well described by their phenotypic and functional plasticity.spa
dc.identifierhttps://investigadores.uandes.cl/en/publications/db4ef133-26f8-419f-bf39-7afe005a0786
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/55115
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.9 (2020) nr.7 p.1-21
dc.subjectTh17 cells
dc.subjectimmunoregulation
dc.subjectmesenchymal stem cells
dc.subjectimmunoregulation
dc.subjectmesenchymal stem cells
dc.subjectTh17 cells
dc.subjectSDG 3 - Good Health and Well-being
dc.titleMechanisms behind the immunoregulatory dialogue between mesenchymal stem cells and th17 cellseng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE